Does lowering lipid levels really affect risk for prostate cancer and prostate cancer-specific mortality?

As our regular readers will be well aware, there have been a number of published papers suggesting associations between the use of statins and other lipid-lowering agents and risk for diagnosis with and progression of prostate cancer over time. … READ MORE …

PCaI joins with Cancer ABCs to advocate for protection of access to cancer and other drugs

For many years now, here in the USA, access to FDA-approved drugs for the treatment of cancer and other severe forms of disorder have been guaranteed under Medicare. … READ MORE …

Can RP + EBRT + ADT provide equal outcomes to brachy boost therapy + ADT in high-risk men?

As we have seen previously (see this link), among men with Gleason 9 or 10 disease, brachy boost therapy (BBT) provided better oncological outcomes compared to either radical prostatectomy (RP) alone or external beam radiation therapy (EBRT) alone. … READ MORE …

Is Problem X really a side effect of ADT, or not …?

We have long been bedeviled by questions about some of the short- and the long-term side effects and complications of androgen deprivation therapy (ADT) in the treatment of prostate cancer. … READ MORE …

First-line treatment for prostate cancer and use of antidepressants

According to a recently reported study in the journal European Urology, men who received first-line surgery or radiation therapy for non-metastatic prostate cancer were significantly more likely to have taken an antidepressant 5 years later than comparable men who didn’t get such treatment. … READ MORE …

Understanding “cell-free DNA analysis” in cancer diagnosis and management

We have probably all heard terms like “liquid biopsy” and “genetic screening” and “cell-free” DNA analysis over the past few years. These are all terms related to the use of genetic and genomic information to “personalize” cancer diagnosis and its management. And they are potentially a huge big deal. But, … READ MORE …

Medicare to cover costs of new test for AR-V7

We have recently learned that Medicare will be covering the costs of the Oncotype DX AR-V7 Nucleus Detect™ test for patients with metastatic, castration-resistant prostate cancer (mCRPC) as of December 10, 2018. … READ MORE …